Navigation Links
BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
Date:4/17/2008

SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.

"We are encouraged by the enthusiasm expressed by our clinical investigators who view BCI-540 as a potential alternative to today's widely prescribed treatments for depression," noted Carrolee Barlow, M.D., Ph.D., Chief Scientific Officer at BCI. "Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels. We are excited about the potential of this compound to change the way mood disorders are treated."

The twelve-week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80 mg given once or three times daily is effective in the treatment of depression with anxiety versus placebo.

"BCI is utilizing our understanding of the power of neurogenesis coupled with our proprietary neurogenic platform technology to identify a strong portfolio of clinical candidates, such as BCI-540, that we plan to move into the clinic this year," said Jim Schoeneck, CEO at BCI. "Moving BCI-540 into the clinic is an important milestone and we are now actively enrolling patients and anticipate completing enrollment by the end of this year."

About BrainCells Inc.

BrainCells Inc. (BCI) is a San Diego-based drug discovery and development company that is applying its proprietary neurogenesis platform technology to identify and reposition compounds for the treatment of central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of CNS indications. For more information, visit http://www.braincellsinc.com.

Media Contact:

BrainCells Inc.

Kim Richards

Porter Novelli Life Sciences

619-849-5377

krichards@pnlifesciences.com


'/>"/>
SOURCE BrainCells Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
4. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
7. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
8. Metabolex Initiates Phase 1 Trial of MBX-2982
9. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
10. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 astic drugs develop from traditional single ... aiming at functions at multiple links. Research and development ... stage. Download the full report: https://www.reportbuyer.com/product/4696059/ ... million cases of new tumors in China ... pollution caused by industrialization and lifestyles changed by factors ...
(Date:2/22/2017)... 22, 2017 Summary Provides ... and agreements entered into by the worlds leading ... http://www.reportlinker.com/p03605675-summary/view-report.html Description The Global Atherosclerosis Partnering ... and access to partnering deals and agreements entered ... - Trends in partnering deals - ...
(Date:2/22/2017)... Summary Provides understanding and access ... entered into by the worlds leading healthcare companies. ... The Global Motor Neurone Disease Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... - Top deals by value - Deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... IL (PRWEB) , ... February 22, 2017 , ... South ... is proud to once again feature Heroes On The Water (HOW), a non-profit organization ... season’s all new episode has series host ‘Mike D’ traveling to Lake Denmark, New ...
(Date:2/22/2017)... ... 22, 2017 , ... A cylindrical “pipeline” used for treating ... reach ones, according to the results of a clinical trial announced Wednesday. , ... Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist Health and Lyerly Neurosurgery ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Using the power ... utilizing a simple online checklist. Over a period of just 24 months, thousands of ... of an online checklist called T.A.D. , “The internet is not getting quieter. In ...
(Date:2/22/2017)... MADISON HEIGHTS, MICHIGAN (PRWEB) , ... February 22, ... ... news and analysis of issues related to spine practices, is featuring Michigan neurosurgeon ... Jagannathan is known as one of a small number of neurosurgeons in Michigan ...
(Date:2/22/2017)... Switzerland (PRWEB) , ... February 22, 2017 , ... ... difficulty hearing and 72 percent of those report that family members or friends ... who think they suffer from hearing loss wear hearing aids. One reason, suggested ...
Breaking Medicine News(10 mins):